The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention
Introduction
The use of MDMA (3,4-methylenedioxymethamphetamine; ecstasy) is a growing public health concern due to its increasing use, association with polysubstance use, various health consequences, and potential neurotoxic effects on the human brain (Johnston et al., 2007a, Maxwell, 2005, Parrott, 2006, Parrott, 2007). MDMA's reported associations with polysubstance use, as well as its likely negative effects, have important implications for prevention and treatment. It is, however, uncertain whether MDMA users should be targeted for focused interventions to reduce the adverse consequences of polysubstance use. Little is presently known about the extent to which MDMA users are characterized by a severe pattern of substance abuse and whether early case finding and interventions with this population are warranted. Given the recent increase in MDMA use among adults (Substance Abuse and Mental Health Services Administration [SAMHSA], 2007), better understanding of the prevention and treatment needs of this population is needed.
In the United States, MDMA is commonly known as one of several “club drugs” (e.g., MDMA/ecstasy, methamphetamine, d-lysergic acid diethylamide or LSD, gamma-hydroxybutyrate or GHB, and ketamine) (Wu, Schlenger, & Galvin, 2006). In the 1990s, the drug appeared to be used predominantly by whites and party or club participants (Koesters et al., 2002, Maxwell, 2005), but MDMA use later spread to nonwhite groups (e.g., Hispanics and blacks) and non-club settings (Maxwell, 2005). National surveys of Americans show a significant upsurge in MDMA use during the late 1990s and early 2000s (Johnston et al., 2007b, Substance Abuse and Mental Health Services Administration, 2007). Nationally, rates of MDMA-related mortality and admissions to emergency departments also increased substantially from 1994 to 2001 (Patel et al., 2004, Substance Abuse and Mental Health Services Administration, 2002). Probably due to increased reports of MDMA-related health consequences and mortality, its use had declined since then. However, the 2006 and 2007 Monitoring the Future surveys indicate that MDMA is the only illicit drug currently demonstrating evidence of an increase in use and a concomitant decline in perceptions of associated risks (Johnston et al., 2007a, Johnston et al., 2007b). Similarly, the 2006 National Survey on Drug Use and Health (NSDUH) reports that the number of new past-year MDMA users increased substantially from approximately 642,000 in 2003 to 860,000 in 2006 (SAMHSA, 2007).
Epidemiological studies suggest that MDMA users are also likely to use cigarettes, alcohol, and other drugs (Carlson et al., 2005, Parrott, 2001, Parrott, 2007, Strote et al., 2002, Topp et al., 1999, Wu et al., 2006). The 2002 NSDUH showed that the majority of past-year MDMA users reported a history of use of alcohol (99%), marijuana (98%), prescription opioids (63%), cocaine (57%), and inhalants (45%) (Wu et al., 2006). Another study of a purposive sample of 402 MDMA users recruited from Ohio (Carlson et al., 2005) also reported a high prevalence of use of other substances: alcohol (100%), marijuana (99%), cigarettes (91%), prescription opioids (80%), cocaine (63%), and inhalants (58%). In Australia, similarly high rates of history of polysubstance use have been observed among MDMA users (Topp et al., 1999).
Despite the widely reported concern over polysubstance use by MDMA users and its potential influence on functional deficits and structural changes to the brain (Parrott, 2006, Reneman et al., 2006), the extent of specific current substance use disorders (SUDs) among MDMA users is unknown. Previous studies have focused mainly on substance use per se (e.g., Carlson et al., 2005, Parrott, 2001, Strote et al., 2002, Scholey et al., 2004, Topp et al., 1999, Wu et al., 2006)—a crude measure that provides limited information concerning the intensity and magnitude of problems related to the use of specific substances among MDMA users. As a result, there is limited information concerning whether MDMA users actually constitute a unique group of polysubstance abusers who are distinct from users of other drugs and whether MDMA users may be particularly adversely affected by the concomitant abuse of other substances (Parrott et al., 2007, Gouzoulis-Mayfrank and Daumann, 2006, Parrott, 2006). Such information has important implications for designing appropriate intervention and prevention programs, as well as selecting MDMA users for clinical research.
In this study, we investigate the 12-month prevalence of specific Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV SUDs (American Psychiatric Association, 2000) and their associations with MDMA use within the context of a nationally representative sample of American adults aged 18 years or older. The focus on adults is based on the findings that the vast majority (70%) of new MDMA users are aged 18 years or older (SAMHSA, 2007). We examine past-year measures of SUDs and MDMA use because they are indicators of recent or active use and because the information they provide is highly relevant to the design of early intervention and treatment programs. Additionally, while the onset of drug use prior to adulthood constitutes a risk factor for developing SUDs (Grant & Dawson, 1998), previous studies have not addressed the association between SUDs and the early onset of MDMA use. Thus, we also examine whether MDMA users who initiated use early in life are associated with increased odds of SUDs than drug users who began use later or who have never used MDMAs.
The 2006 NSDUH is the most recent year available and demonstrates the significant upsurge in MDMA use among adults (SAMHSA, 2007). These data provide an excellent means for identifying the characteristics of recent MDMA users and for determining whether MDMA use occurs among casual (e.g., experimental) or more problematic substance users. This data source also constitutes the nation's largest study of drug use, thus providing sufficient statistical power to allow us to control for the potentially confounding effects of prior MDMA use among users of drugs other than MDMA by investigating SUDs across groups stratified by MDMA and other drug use. Because it is representative of domiciled adults in the U.S., this large sample also permits the generalizability of study findings.
We address three main questions. First, what are the sociodemographic and mental health characteristics of past-year MDMA users, and are these characteristics distinct from those of former MDMA users and users of drugs other than MDMA? Second, are there higher prevalence rates of SUDs among past-year MDMA users than among former MDMA users and other drug users? Third, are past-year and early-onset MDMA use still associated with SUDs after statistically controlling potential confounds such as socioeconomic status, mental health, age of first drug use, and history of polydrug usage.
Section snippets
Study sample
This study is based on data from adult respondents contained in the public use file of the 2006 NSDUH (SAMHSA, 2007). NSDUH is the only ongoing survey that provides population estimates of substance use, SUDs, and health in the U.S. population. The survey's sampling frame covers approximately 98% of the total U.S. population aged 12 years or older and uses multistage area probability sampling methods to select a representative sample of the civilian non-institutionalized population.
MDMA users vs. other drug users
Out of 36,965 adult respondents, approximately 14% reported drug use in the past year. We found that 0.8% of the sample comprised recent MDMA users who had used MDMA in the past year, 2.5% were former MDMA users who had used drugs other than MDMA in the past year, and 10.5% were other drug users who had never used MDMA (Table 1).
Compared with non-drug users, past-year drug users (irrespective of MDMA use) were more likely to be male, white, under age 35, single, and to report anxiety disorder
Discussion
This study reports new findings on specific DSM-IV SUDs in a large nationally representative sample of adult MDMA users. In 2006, approximately one in seven adults reported drug use in the past year. Of these drug users, close to 6% had used MDMA in the past year, and 18% had used it prior to the past year. Both groups of MDMA users reported a higher prevalence of several SUDs than did other drug users. Even after controlling for potentially important confounders, recent MDMA users not only
Acknowledgments
This work was supported by research grants from the U.S. National Institute on Drug Abuse of the National Institutes of Health (DA019623 and DA019901; Principal Investigator Li-Tzy Wu). The opinions expressed in this paper are solely those of the authors and not of the sponsoring agency. The sponsoring agency had no further role in study design and analysis, in the writing of the report, or in the decision to submit the paper for publication. The Substance Abuse and Mental Health Data Archive
References (55)
- et al.
Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?
Drug and Alcohol Dependence
(2008) - et al.
Prescription opioid abuse in patients presenting for methadone maintenance treatment
Drug and Alcohol Dependence
(2004) - et al.
Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis
Drug and Alcohol Dependence
(2005) Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment
Addictive Behaviors
(1978)- et al.
Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey
Journal of Substance Abuse
(1998) - et al.
MDMA (‘ecstasy’) and other ‘club drugs’. The new epidemic
Pediatric Clinics of North America
(2002) - et al.
Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use
Drug and Alcohol Dependence
(2007) - et al.
Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study
Addictive Behaviors
(2004) - et al.
Increasing MDMA use among college students: results of a national survey
Journal of Adolescent Health
(2002) - et al.
Ecstasy use in Australia: patterns of use and associated harm
Drug and Alcohol Dependence
(1999)
Exposure opportunity as a mechanism linking youth marijuana use to hallucinogen use
Drug and Alcohol Dependence
Drugs and the dance music scene: a survey of current drug use patterns among a ample of dance music enthusiasts in the UK
Drug and Alcohol Dependence
Inhalant abuse and dependence among adolescents in the United States
Journal of the American Academy of Child and Adolescent Psychiatry
Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths
Drug and Alcohol Dependence
Prescription pain reliever abuse and dependence among adolescents: a nationally representative study
Journal of the American Academy of Child and Adolescent Psychiatry
Diagnostic and Statistical Manual of Mental Disorders
Handbook of the Medical Consequences of Alcohol and Drug Abuse
Rolling beyond the raves: ecstasy use outside the rave setting
Journal of Drug Issues
Understanding reasons for drug use amongst young people: a functional perspective
Health Education Research
The natural history of drug use from adolescence to the mid-thirties in a general population sample
American Journal of Public Health
Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria
Human Psychopharmacology
New perspectives on adolescent risk behavior
The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview
Journal of Psychopharmacology
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
Journal of Neurology, Neurosurgery and Psychiatry
The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire
British Journal of Addiction
Overall, illicit drug use by American teens continues gradual decline in 2007
Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2006 (NIH Publication No. 07-6202)
Cited by (16)
Intentions, actions and outcomes: A follow up survey on harm reduction practices after using an English festival drug checking service
2021, International Journal of Drug PolicyCitation Excerpt :Whilst drug-related deaths (DRDs) are a key harm and their prevention is a primary goal, other drug-specific and drug-related harms arise for individual users and wider society from adulteration, misselling and variations in strength, that are the focus here. For example, overdose can result from 25x-NBOMe missold as LSD (Martins et al., 2017; Measham, 2020); anxiety, paranoia and psychosis from potent cathinones such as N-ethylpentylone missold as MDMA (Measham & Jones, 2017); severe toxicity from high dosage (Black et al., 2020); from mixing polydrug use and medications with pre-existing health conditions (Liamis, Milionis, & Elisaf, 2008; Wu et al., 2009); and drug-related hyperthermia and hyponatremia (Campbell & Rosner, 2008). All can result in harm ranging from low-level adverse effects such as nausea through to acute and chronic psychological and physiological problems including permanent organ damage.
Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’)
2020, Brain ResearchCitation Excerpt :It should be emphasised that taking MDMA is a minority activity. In a national USA population survey, only 0.8% of adults reported MDMA usage during the previous year (Wu et al., 2009), while in a similar European survey, 4.1% of adults aged 15–64 stated that they had taken it at least once in their lifetime (0.8% in the previous year), with 95.9% assuring they had never taken it (EMCDDA, 2018). Furthermore, most Ecstasy/MDMA users take it just a few times, with its regular use being comparatively rare, at around 1–2% of the adult population (Parrott et al., 2017).
Cocaine enhances the conditioned rewarding effects of MDMA in adolescent mice
2015, Brain Research BulletinCitation Excerpt :The consumption of MDMA, an amphetamine derivative that improved mood, euphoria and closeness to others, has spread in recent years among adolescents and young adults (UNODC, 2013) and some consumers fulfil the criteria for abuse or dependence (Leung and Cottler, 2008). Although the consumption of cocaine is frequent among MDMA users (Wu et al., 2009a) and increases the likelihood to develop drug use disorders (Wu et al., 2009b), no study has evaluated the influence of previous or simultaneous consumption of cocaine on the rewarding effects of MDMA in adolescents. In animal models of reward, both drugs are capable of inducing self-administration (Roberts et al., 2013; Schenk, 2009) and conditioned place preference (CPP) (Aguilar et al., 2009; Roger-Sánchez et al., 2013a) when administered independently, having cross-reinstatement between them in the self-administration paradigm (Schenk et al., 2008; Trigo et al., 2009).
What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?
2011, Neuroscience and Biobehavioral ReviewsCitation Excerpt :It seems, therefore, that while cannabis may not necessarily improve the neuropsychological effects caused by methamphetamine, at least it does not make them worse. It is common for MDMA users to consume other substances, the most frequent of which is cannabis (Wu et al., 2009). We found four studies that have tried to dissociate the neuropsychological effects stemming from the MDMA and cannabis co-use by means of subtraction techniques.
Hallucinogen-related disorders in a national sample of adolescents: The influence of ecstasy/MDMA use
2009, Drug and Alcohol Dependence